OakChart

NewcelX Ltd

NCELHealthcare·Biotechnology·Switzerland·Nano·NASD·Nov 11 • 3:59 PM ET

2.80-0.06 (-2.10%)
2026-11-12 04:07 CET
Market cap
15.07 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-5.63 USD m
Free cash flow, TTM
-2.87 USD m
EPS diluted, TTM
-0.96
P/E
-
Compare

Price

NCEL against its 20, 50 and 200-day averages
2050200earnings
2.004.006.008.00462K925KVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26NCELclose 2.8020-day 2.6950-day 2.93200-day 3.112.8052w high

45.3% under the 52-week high of 5.12 on 24 Apr 2026. 52-week low 1.83 on 30 Mar 2026. Last 15 sessions, 36.3% high to low

Volume 2.18× normal · the line is the 50-bar volume average

Profile

NCEL
52-week range, 29% of the way up
1.835.12

NewCelX Ltd. is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company is headquarter in Kloten, Switzerland.

Employees12
IPOJan 29, 2021
Beta1.05
ATR, 14d0.32
Rel volume2.18
Short float0.41%
Insider own52.90%
Inst own0.25%

Snapshot

6 groups

Valuation

Index-
Market Cap15.08M
Enterprise Value14.76M
Income-
Sales-
Book/sh1.12
Cash/sh0.13
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees12
IPOJan 29, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B2.50
P/C21.24
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio0.32
Current Ratio0.32
Debt/Eq0.06
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y81.39% 60.94%
Sales past 3/5Y- -
EPS Y/Y TTM77.07%
Sales Y/Y TTM-
EPS Q/Q86.03%
Sales Q/Q-
EarningsSep 02
EPS/Sales Surpr.0.00% -

Ownership

Insider Own52.90%
Insider Trans0.00%
Inst Own0.25%
Inst Trans-86.36%
ROA-
ROE-
ROIC-
Gross Margin-
Oper. Margin-
Profit Margin-
SMA204.21%
SMA50-4.29%
SMA200-9.94%
Trades-

Technical

Shs Outstand5.38M
Shs Float2.54M
Short Float0.41%
Short Ratio0.76
Short Interest0.01M
52W High5.12 -45.31%
52W Low1.83 53.01%
Volatility14.87% 14.21%
ATR (14)0.32
RSI (14)50.65
Beta1.05
Rel Volume2.18
Avg Volume13.72K
Volume29,911

Performance

Perf Week9.38%
Perf Month-1.41%
Perf Quarter-22.22%
Perf Half Y-13.58%
Perf YTD47.37%
Perf Year-25.33%
Perf 3Y-98.91%
Perf 5Y-99.65%
Perf 10Y-
Recom1.00
Target Price23.00
Prev Close2.86
Price2.80
Change %-2.10%

Peers

Mkt cap
TickerCompanyMkt cap
LGVNLongeveron Inc10.52M
SANASana Biotechnology Inc686.16M
ENLVEnlivex Ltd1.93M
NRSNNeuroSense Therapeutics Ltd3.38M
PLURPluri Inc15.13M
CLNNClene Inc60.40M
BCDABioCardia Inc13.95M
BRTXBioRestorative Therapies Inc2.15M
CELZCreative Medical Technology Holdings Inc4.79M
MESOMesoblast Ltd ADR1.78B

Insider trading

2 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Samuel OlivierDirectorApr 27 '26Buy2.7581,818225,00081,818Apr 29 04:05 PM
Revel MichelCSO and DirectorApr 27 '26Buy2.7554,545149,999957,530Apr 29 04:05 PM

News

latest 14 of 200
  • NewcelX Announces Pricing of $1.55 Million Equity Financing at 20% Premium Pricing to Market (GlobeNewswire)
  • NewcelX Enters into Binding Term Sheet to Divest Legacy Mazindol Portfolio (CVR), Providing for Upfront Cash, Equity Ownership and Up to $55 Million in Potential Milestone Payments (GlobeNewswire)
  • NewCelX Management to Attend Breakthrough T1D Congress in Philadelphia, Advancing Its Mission to Develop a Cure for Type 1 Diabetes (GlobeNewswire)
  • NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing (GlobeNewswire)
  • NewcelX Granted Patent in Brazil for NCEL-101 in Type 1 Diabetes, Expanding Global IP Portfolio (GlobeNewswire)
  • NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board (GlobeNewswire) +5.49%
  • The Longevity Protein Race Reaches Manufacturing: One Microcap Just Completed A GMP Master Cell Bank For Its Anti-Aging Klotho Therapy (PR Newswire)
  • NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes (GlobeNewswire) +5.19%
  • NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes (GlobeNewswire) +9.52%
  • NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026 (GlobeNewswire) +28.95%
  • NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference (GlobeNewswire) +6.39%
  • NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing (GlobeNewswire) +10.85%
  • NewcelX and Eledon partner for NCEL-101 programme (Pharmaceutical Business Review)
  • NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes (PR Newswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026S12026-09-02-0.530-0.530-0.961--1
2023S12023-08-30-68.000--79.764---
2026S2---0.650---1

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-192-140-237.50.00-
2021FY-400-300-323.990.000.00
2022FY-152--0.00-
2025FY-2.160--0.00-
2026FY--1.180---
2027FY--0.600---
2028FY--0.740---
2029FY--0.660---
2030FY--0.730---

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026S2E2026-09-02100-0.65-0.65-0.65
2026S2E2026-07-10100-0.65-0.65-0.65
2026FYE2026-07-10100-1.18-1.18-1.18
2023S2R2023-12-21100-8.40-8.40-8.40
2023S2R2023-12-20100-8.40-8.40-8.40
2023S2R2023-12-19100-8.40-8.40-8.40
2023S2R2023-12-18100-8.40-8.40-8.40
2023S2R2023-12-17100-8.40-8.40-8.40
2023S2R2023-12-16100-8.40-8.40-8.40
2023S2R2023-12-13100-8.40-8.40-8.40
2023S2R2023-12-12100-8.40-8.40-8.40
2023S2R2023-12-11100-8.40-8.40-8.40
2023S2R2023-12-10100-8.40-8.40-8.40
2023S2R2023-12-09100-8.40-8.40-8.40

Estimate history

EPS, annual-184.772-195.556-237.5-323.992-335.232-127.536-24.32-2.159
Period20182019202020212022202320242025
EPS, quarterly
Period
Sales, annual00000000
Period20182019202020212022202320242025
Sales, quarterly
Period
Shares, annual0.0280.0280.0120.0370.0810.0810.2964.798
Period20182019202020212022202320242025
Shares, quarterly
Period

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.020.060.110.010.010.010.000.000.00
Gross Profit-0.02-0.06-0.11-0.01-0.01-0.010.000.000.00
Selling, General and Administrative Excl. Other2.812.421.6911.8015.4711.852.304.203.45
Research and Development1.171.130.995.918.985.920.101.701.44
Other Operating Expense0.000.090.270.000.000.000.000.000.00
Operating Income-2.83-2.56-2.07-11.81-15.48-11.86-2.30-4.20-3.45
Interest Expense0.106.115.140.150.100.070.230.821.08
Unusual Expense0.000.000.000.000.920.000.000.360.63
Net Income Before Taxes-2.90-8.30-7.20-12.17-16.50-11.95-2.86-5.45-5.15
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-2.90-8.30-7.20-12.17-16.50-11.95-2.86-5.45-5.15
Net Income From Continuing Operations-2.90-8.30-7.20-12.17-16.50-11.95-2.86-5.45-5.15
Net Income-5.63-8.30-7.20-12.17-16.50-11.95-2.86-5.45-5.15
EPS (Recurring)-0.96-2.16-24.32-127.54-322.11-323.99-237.50-186.39-168.96
EPS (Basic, Before Extraordinaries)-0.96-2.16-24.32-127.54-335.23-323.99-237.50-195.56-184.77
EPS (Diluted)-0.96-2.16-24.32-127.54-335.23-323.99-237.50-195.56-184.77
EBITDA-2.81-2.51-1.96-11.80-15.47-11.85-2.30-4.20-3.45
Non-Operating Income (Expense)0.040.370.01-0.220.01-0.02-0.33-0.070.02
Other After Tax Adjustments-0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.280.770.210.160.02----
Shares Outstanding5.384.800.300.080.080.040.010.030.03
Market Capitalization15.0715.0752.178,417.1214,166.065,358.335,551.42--

Income statement, quarterly

Currency USD, millions
Metric2026S12025S12024S22024S12023S22023S12022S22022S1
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.020.000.000.010.010.010.010.01
Gross Profit-0.02-0.000.00-0.01-0.01-0.01-0.01-0.01
Selling, General and Administrative Excl. Other2.811.781.582.054.257.546.798.68
Research and Development1.170.140.150.271.524.383.435.54
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-2.83-1.78-1.58-2.05-4.26-7.55-6.79-8.69
Interest Expense0.100.000.060.090.150.000.090.01
Unusual Expense0.000.42-1.760.000.000.000.920.00
Net Income Before Taxes-2.90-2.220.06-2.04-4.56-7.61-7.85-8.64
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-2.90-2.220.06-2.04-4.56-7.61-7.85-8.64
Net Income From Continuing Operations-2.90-2.220.06-2.04-4.56-7.61-7.85-8.64
Net Income-5.63-4.19-2.02-2.04-4.56-7.61-7.85-8.64
EPS (Recurring)-0.96-9.73-11.05-19.41-56.24-79.76-108.07-217.48
EPS (Basic, Before Extraordinaries)-0.96-10.47-6.87-19.42-56.24-79.76-117.75-217.48
EPS (Diluted)-0.96-10.47-6.87-19.42-56.24-79.76-117.75-217.48
EBITDA-2.81-1.78-1.59-2.05-4.25-7.54-6.79-8.68
Non-Operating Income (Expense)0.04-0.02-0.060.10-0.16-0.06-0.050.06
Stock Option Compensation Expense0.280.050.070.060.100.060.02-
Shares Outstanding5.380.420.320.100.080.080.080.04
Market Capitalization15.07104.3352.173,764.108,417.1214,268.7214,166.064,518.81

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments2.200.650.908.955.430.090.220.01
Short Term Receivables0.000.000.010.000.000.000.080.01
Inventories0.000.000.000.000.000.000.000.00
Other Current Assets0.690.130.910.300.290.100.090.07
Total Current Assets2.890.781.829.255.720.200.380.09
Net Property, Plant & Equipment0.100.120.010.020.030.000.000.00
Total Investments and Advances0.000.000.000.000.000.000.000.00
Long-Term Note Receivable----0.000.070.050.06
Intangible Assets8.170.00---0.000.000.00
Other Assets0.300.000.020.010.010.950.260.00
Total Assets11.450.901.859.285.761.210.700.15
Short Term Debt Incl. Current Port. of LT Debt0.357.731.630.000.001.770.690.71
Accounts Payable1.030.214.632.371.744.012.511.13
Income Tax Payable1.670.00------
Other Current Liabilities1.130.971.650.990.671.430.840.58
Total Current Liabilities4.208.907.923.362.407.204.042.41
Long Term Debt0.000.000.000.000.000.310.156.39
Provision for Risks Charges0.000.000.260.140.320.180.180.16
Other Liabilities0.000.002.502.502.502.502.500.00
Total Liabilities4.208.9010.686.005.2210.206.878.96
Non-Equity Reserves0.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.00
Common Equity7.25-8.00-8.833.280.54-8.98-6.17-8.81
Total Shareholders Equity7.25-8.00-8.833.280.54-8.98-6.17-8.81
Accumulated Minority Interest0.000.000.000.000.000.000.000.00
Total Equity7.25-8.00-8.833.280.54-8.98-6.17-8.81
Total Liabilities & Stockholders Equity11.450.901.859.285.761.210.700.15
Book Value Per Share1.51-27.01-108.9640.4714.71-745.68-221.54-316.42
Tangible Book Value Per Share-0.19-27.01-108.9640.4714.71-745.68-221.54-316.42
Full-Time Employees123426644
Price to Book Ratio2.50-89.76-1,785.01-2,270.8312,071.781,306.56--
Return on Assets-121.36-523.49-218.86-219.34-342.48-299.94-1,293.76-
Return on Equity-191.77---862.92----
Return on Invested Capital-114.48---502.79-2,202.50---
Quick Ratio0.690.090.232.752.380.030.090.04
Current Ratio0.690.090.232.752.380.030.090.04

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-2.90-8.30-7.20-12.17-16.50-11.95-2.86-5.45-5.15
Depreciation0.020.060.110.010.010.01---
Other Funds (Non Cash)0.386.555.290.220.980.170.071.141.75
Funds from Operations-2.50-1.70-1.80-11.94-15.51-11.77-2.79-4.31-3.40
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-0.37-1.070.742.251.63-3.172.064.120.67
Cash from Operating Activities-2.87-2.77-1.07-9.68-13.88-14.94-0.73-0.19-2.73
Capital Expenditures0.00-0.01-0.010.000.00-0.040.000.000.00
Net Assets From Acquisitions0.001.710.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities0.001.70-0.010.000.00-0.040.000.000.00
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Preferred Dividends (Cash Flow)--0.000.000.000.000.000.000.00
Change in Capital Stock1.372.340.000.0018.1018.890.000.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock1.372.340.000.0018.1018.890.000.000.00
Proceedsfrom Stock Options1.350.000.000.0010.7211.000.000.000.00
Issuance or Reduction of Debt, Net0.000.290.451.63-0.70-2.101.190.670.56
Change in Long Term Debt0.000.000.000.000.000.00---
Issuance of Long Term Debt0.000.000.000.000.000.00---
Reduction of Long Term Debt0.000.000.000.000.000.00---
Net Financing Active Other Cash Flow0.000.000.000.000.003.55-0.69-0.260.00
Other Financing Activities Uses0.000.000.000.000.000.00-0.69-0.260.00
Cash from Financing Activities1.372.630.451.6317.4020.340.500.410.56
Exchange Rate Effect0.02-0.01-0.040.00-0.00-0.020.10-0.00-0.00
Net Change in Cash-1.491.55-0.67-8.053.525.34-0.130.21-2.18
Free Cash Flow-2.87-2.77-1.07-9.68-13.88-14.98-0.73-0.19-2.73
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026S12025S12024S22024S12023S22023S1
Cash & Short Term Investments0.713.071.670.550.901.65
Short Term Receivables0.000.540.400.030.010.00
Inventories0.000.000.000.000.000.00
Other Current Assets0.450.430.160.610.910.59
Total Current Assets1.164.042.231.191.822.25
Net Property, Plant & Equipment0.080.010.010.000.010.01
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets8.17--0.00--
Other Assets0.300.300.000.000.020.01
Total Assets9.704.342.231.191.852.27
Short Term Debt Incl. Current Port. of LT Debt0.390.000.001.711.630.00
Accounts Payable0.961.020.524.584.633.11
Income Tax Payable1.67-----
Other Current Liabilities0.630.430.311.421.650.78
Total Current Liabilities3.661.460.837.727.923.89
Long Term Debt0.000.000.000.000.000.00
Other Liabilities0.000.000.002.502.502.50
Total Liabilities3.661.460.8310.4610.686.56
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.062.740.000.000.00
Common Equity6.042.82-1.33-9.27-8.83-4.29
Total Shareholders Equity6.042.881.41-9.27-8.83-4.29
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity6.042.881.41-9.27-8.83-4.29
Total Liabilities & Stockholders Equity9.704.342.231.191.852.27
Book Value Per Share1.126.79-4.22-94.02-108.96-52.88
Tangible Book Value Per Share-0.406.79-4.22-94.02-108.96-52.88
Price to Book Ratio2.50-68.66-89.76-318.50-1,785.01-3,328.54
Return on Assets--78.31-97.10-380.82-218.86-714.74
Return on Invested Capital-48.01-77.043.91---
Quick Ratio0.322.772.690.150.230.58
Current Ratio0.322.772.690.150.230.58

Cash flow, quarterly

Currency USD, millions
Metric2026S12025S12024S22024S12023S22023S1
Net Income-2.90-2.220.06-2.04-4.56-7.61
Depreciation0.020.00-0.000.010.010.01
Other Funds (Non Cash)0.380.05-2.470.100.180.05
Funds from Operations-2.50-2.17-2.41-1.93-4.37-7.56
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.370.10-0.320.401.990.27
Cash from Operating Activities-2.87-2.07-2.74-1.53-2.39-7.30
Capital Expenditures0.000.00-0.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.00-0.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)---0.000.000.00
Change in Capital Stock1.373.483.661.380.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock1.373.483.661.380.000.00
Proceedsfrom Stock Options1.353.303.491.380.000.00
Issuance or Reduction of Debt, Net0.000.000.19-0.190.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities1.373.483.851.191.630.00
Exchange Rate Effect0.02-0.000.000.00-0.00
Net Change in Cash-1.491.411.11-0.34-0.75-7.30
Free Cash Flow-2.87-2.07-2.74-1.53--

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.41%0.0M2.5M8.60K
2026-10-150.39%0.0M2.5M8.67K
2026-09-300.38%0.0M2.5M17.61K
2026-09-150.59%0.0M2.5M18.71K
2026-08-310.78%0.0M2.5M20.74K
2026-08-141.47%0.0M2.5M36.44K
2026-07-311.56%0.0M2.5M38.82K
2026-07-152.25%0.1M2.5M58.76K
2026-06-302.23%0.1M2.5M52.18K
2026-06-152.39%0.1M2.5M51.77K
2026-05-293.73%0.1M2.0M54.19K
2026-05-152.08%0.0M2.4M38.43K
2026-04-302.32%0.1M2.4M41.57K
2026-04-151.56%0.0M3.1M34.72K
2026-03-310.85%0.0M4.1M88.66K
2026-03-130.88%0.0M4.1M95.57K
2026-02-272.37%0.1M4.1M111.86K
2026-02-132.62%0.1M4.1M115.05K
2026-01-302.16%0.1M4.1M150.08K
2026-01-152.99%0.1M4.1M241.24K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-096-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-09SEC
2026-11-096-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-09SEC
2026-11-046-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-04SEC
2026-09-22EFFECTEffectiveness filing by commission orderSEC
2026-09-18POS AMPost-effective amendment to a registration statement that is not immediately effective upon filingSEC
2026-09-186-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC
2026-08-26EFFECTEffectiveness filing by commission orderSEC
2026-08-24DNotice of sales of securities on Form D (Regulation D)SEC
2026-08-20F-3Registration statement for specified transactions by certain foreign private issuersSEC
2026-08-036-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-03SEC
2026-07-316-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-31SEC
2026-07-156-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-15SEC
2026-07-086-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-08SEC
2026-07-016-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-01SEC
2026-06-306-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC
2026-06-17EFFECTEffectiveness filing by commission orderSEC
2026-06-156-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-15SEC
2026-06-10F-3/ASEC
2026-06-056-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-05SEC
2026-05-276-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-27SEC
2026-05-14CORRESPSEC
2026-05-14UPLOADUpload SubmissionSEC
2026-05-13DNotice of sales of securities on Form D (Regulation D)SEC
2026-05-11F-3Registration statement for specified transactions by certain foreign private issuersSEC
2026-05-06EFFECTEffectiveness filing by commission orderSEC
2026-05-05POS AMPost-effective amendment to a registration statement that is not immediately effective upon filingSEC
2026-05-04SCHEDULE 13DSEC
2026-04-306-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-30SEC
2026-04-2920-FRegistration statement under Section 12 of the Securities Exchange Act of 1934 or an annual or transition report filed under Section 13(a) or 15(d) of the Exchange Act for a foreign private issuer.2025-12-31SEC
2026-04-294Statement of changes in beneficial ownership of securities2026-04-27SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-04375.00K200
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
HRT FINANCIAL LP0.21%
HARBOUR INVESTMENTS, INC.0.03%
JONES FINANCIAL COMPANIES LLLP0.01%
Caitong International Asset Management Co., Ltd0.00%
CoreCap Advisors, LLC0.00%

Funds

Fund% owned
-

OakChart. NCEL. Cached 15 minutes.

Some panels did not load: ratings.